PubMed

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG.

Br J Haematol. 2009 Nov 6. [Epub ahead of print]PMID: 19895616 [PubMed - as supplied by publisher]Related articles

Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.

Thomas DA, Ravandi F, Keating M, Kantarjian HM.

Leuk Lymphoma. 2009 Oct;50 Suppl 1:27-31.PMID: 19814695 [PubMed - in process]Related articles

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.

Thomas DA, O'Brien S, Kantarjian HM.

Hematol Oncol Clin North Am. 2009 Oct;23(5):949-71, v.PMID: 19825447 [PubMed - in process]Related articles

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.

Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM.

Leukemia. 2009 Oct 1. [Epub ahead of print]PMID: 19798095 [PubMed - as supplied by publisher]Related articles

JAK2 inhibitors: A reality? A hope?

Apostolidou E, Kantarjian HM, Verstovsek S.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S340-5.PMID: 19778862 [PubMed - in process]Related articles

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.

Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ.

Mol Cancer Ther. 2009 Sep;8(9):2509-16. Epub 2009 Sep 1.PMID: 19723894 [PubMed - in process]Related articles

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J; Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group.

J Clin Oncol. 2009 Oct 1;27(28):4754-9. Epub 2009 Aug 31.PMID: 19720924 [PubMed - indexed for MEDLINE]Related articles

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S.

J Clin Oncol. 2009 Oct 1;27(28):4760-6. Epub 2009 Aug 31.PMID: 19720904 [PubMed - indexed for MEDLINE]Related articles

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.

Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S.

Cancer. 2009 Dec 1;115(23):5490-8.PMID: 19708032 [PubMed - in process]Related articles

Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation.

Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE.

Cancer. 2009 Dec 1;115(23):5481-9.PMID: 19672946 [PubMed - in process]Related articles

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.

Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE.

J Hematop. 2009 Mar;2(1):2-8. Epub 2008 Nov 4.PMID: 19669217 [PubMed - in process]Related articlesFree article

Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM.

J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3.PMID: 19652059 [PubMed - indexed for MEDLINE]Related articles

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP.

Leukemia. 2009 Sep;23(9):1628-33. Epub 2009 Jul 30.PMID: 19641527 [PubMed - indexed for MEDLINE]Related articles

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.

Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE.

Cancer. 2009 Oct 15;115(20):4737-44.PMID: 19637342 [PubMed - in process]Related articles

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J.

Blood. 2009 Sep 3;114(10):2037-43. Epub 2009 Jun 30.PMID: 19567878 [PubMed - indexed for MEDLINE]Related articles

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J.

Blood. 2009 Sep 10;114(11):2232-5. Epub 2009 Jun 16.PMID: 19531657 [PubMed - indexed for MEDLINE]Related articles

Introduction: targeting different pathways to prevent tumor cell development.

Kantarjian HM.

Semin Oncol. 2009 Apr;36(2 Suppl 1):S1-5. No abstract available. PMID: 19393830 [PubMed - indexed for MEDLINE]Related articles

Targeting DNA methylation.

Issa JP, Kantarjian HM.

Clin Cancer Res. 2009 Jun 15;15(12):3938-46. Epub 2009 Jun 9.PMID: 19509174 [PubMed - indexed for MEDLINE]Related articles

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.

Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D.

J Clin Oncol. 2009 Aug 1;27(22):3642-9. Epub 2009 Jun 8.PMID: 19506164 [PubMed - indexed for MEDLINE]Related articles

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.

Kantarjian HM, Shan J, Jones D, O'Brien S, Rios MB, Jabbour E, Cortes J.

J Clin Oncol. 2009 Aug 1;27(22):3659-63. Epub 2009 Jun 1.PMID: 19487383 [PubMed - indexed for MEDLINE]Related articles

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood. 2009 Jul 2;114(1):144-7. Epub 2009 May 6.PMID: 19420352 [PubMed - indexed for MEDLINE]Related articlesFree article

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.

Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM.

Cancer. 2009 Jul 1;115(13):2912-21.PMID: 19402171 [PubMed - indexed for MEDLINE]Related articles

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.

Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT.

Leukemia. 2009 Sep;23(9):1605-13. Epub 2009 Apr 23.PMID: 19387468 [PubMed - indexed for MEDLINE]Related articles

Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.

Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z.

Cancer Res. 2009 May 1;69(9):3910-7. Epub 2009 Apr 21.PMID: 19383925 [PubMed - indexed for MEDLINE]Related articles

Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.

Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM.

Oncologist. 2009 May;14(5):489-96. Epub 2009 Apr 13. Review.PMID: 19365094 [PubMed - indexed for MEDLINE]Related articles

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

Quintás-Cardama A, Kantarjian HM, Cortes JE.

Cancer Control. 2009 Apr;16(2):122-31. Review.PMID: 19337198 [PubMed - indexed for MEDLINE]Related articlesFree article

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.

Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J.

Blood. 2009 May 21;113(21):5058-63. Epub 2009 Mar 12.PMID: 19282457 [PubMed - indexed for MEDLINE]Related articles

Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens.

Kantarjian HM, O'Brien S.

Blood. 2009 Feb 19;113(8):1861; author reply 1862. No abstract available. PMID: 19228933 [PubMed - indexed for MEDLINE]Related articles

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S.

Leuk Res. 2009 Nov;33(11):1481-4. Epub 2009 Feb 3.PMID: 19193436 [PubMed - indexed for MEDLINE]Related articles

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

Jabbour E, Cortes JE, Kantarjian HM.

Mayo Clin Proc. 2009 Feb;84(2):161-9. Review.PMID: 19181650 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.

Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ; International Randomized Study of Interferon and STI571 (IRIS) Investigators.

Cancer. 2009 Feb 1;115(3):551-60.PMID: 19117345 [PubMed - indexed for MEDLINE]Related articles

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.

Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ.

Cancer. 2009 Jan 15;115(2):373-80.PMID: 19117034 [PubMed - indexed for MEDLINE]Related articles

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ.

J Clin Oncol. 2009 Feb 20;27(6):904-10. Epub 2008 Dec 29.PMID: 19114699 [PubMed - indexed for MEDLINE]Related articles

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.

Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G.

Blood. 2009 Feb 26;113(9):1892-8. Epub 2008 Dec 23.PMID: 19109226 [PubMed - indexed for MEDLINE]Related articles

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J.

Blood. 2009 Mar 5;113(10):2154-60. Epub 2008 Dec 5.PMID: 19060245 [PubMed - indexed for MEDLINE]Related articles

Outcome of adults with acute lymphocytic leukemia after second salvage therapy.

O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM.

Cancer. 2008 Dec 1;113(11):3186-91.PMID: 18846563 [PubMed - indexed for MEDLINE]Related articles

Functional proteomic profiling of AML predicts response and survival.

Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB.

Blood. 2009 Jan 1;113(1):154-64. Epub 2008 Oct 7.PMID: 18840713 [PubMed - indexed for MEDLINE]Related articles

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey E.

Blood. 2009 Jan 1;113(1):28-36. Epub 2008 Sep 30.PMID: 18827183 [PubMed - indexed for MEDLINE]Related articles

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J.

Blood. 2008 Dec 15;112(13):4839-42. Epub 2008 Sep 25.PMID: 18818391 [PubMed - indexed for MEDLINE]Related articles

Clofarabine combinations as acute myeloid leukemia salvage therapy.

Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM.

Cancer. 2008 Oct 15;113(8):2090-6.PMID: 18756533 [PubMed - indexed for MEDLINE]Related articlesFree article

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM.

Blood. 2009 Jun 18;113(25):6330-7. Epub 2008 Aug 14.PMID: 18703706 [PubMed - indexed for MEDLINE]Related articles

Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.

Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E.

Cancer. 2008 Sep 15;113(6):1370-8.PMID: 18623376 [PubMed - indexed for MEDLINE]Related articlesFree article

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.

Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM.

Cancer. 2008 Sep 1;113(5):985-94.PMID: 18615627 [PubMed - indexed for MEDLINE]Related articlesFree article

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S.

Blood. 2008 Sep 1;112(5):1628-37. Epub 2008 Jun 19.PMID: 18566326 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM.

Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18.PMID: 18565853 [PubMed - indexed for MEDLINE]Related articlesFree article

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A.

J Clin Oncol. 2008 Jul 1;26(19):3204-12. Epub 2008 Jun 9.PMID: 18541900 [PubMed - indexed for MEDLINE]Related articles

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP.

Blood. 2008 Aug 15;112(4):1366-73. Epub 2008 Jun 3.PMID: 18523155 [PubMed - indexed for MEDLINE]Related articlesFree article

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.

Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S.

Cancer Sci. 2008 Jun;99(6):1265-73.PMID: 18482053 [PubMed - indexed for MEDLINE]Related articles

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.

Leukemia. 2008 Jun;22(6):1200-6. Epub 2008 Apr 10.PMID: 18401416 [PubMed - indexed for MEDLINE]Related articles

Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators.

Yu Z, Sun B, Kantarjian HM, Keating MJ, Amin HM, Sun X.

Leuk Lymphoma. 2008 Apr;49(4):751-6.PMID: 18398743 [PubMed - indexed for MEDLINE]Related articles